Orbifloxacin, is a fluoroquinolone antibiotic developed for use in veterinary medicine that is quickly and widely distributed after administration and is excreted primarily by kidney. In this study the pharmacokinetics of orbifloxacin after a single oral administration of 5.0 mg/kg body weight was evaluated in three dogs with experimentally induced chronic kidney disease (CKD group) compared to three healthy dogs (healthy group). The mean glomerular filtration rates by inulin clearance for the CKD group and the healthy group were 2.32±0.45 m
l/min/kg and 4.14±0.66 m
l/min/kg respectively. The maximum blood concentration of orbifloxacin was 3.60±0.23 μg/m
l in the healthy group one hour after administration, and 3.07±0.31 μg/m
l in the CKD group two hours after administration. The average blood concentration of orbifloxacin a 24 hours after administration was 0.45±0.14 μg/m
l in the healthy group and 0.41±0.10 μg/m
l in the CKD group. In this study the concentration of orbifloxacin were higher in the CKD group, whereas there was no significant difference compared to the healthy group. In conclusion, orbifloxacin showed favorable pharmacokinetic properties with no obvious adverse reactions in the CKD group compared to the healthy group.Therefore, these results suggest that no dosage adjustment of orbifloxacin is needed for CKD dogs.
View full abstract